PDF(Pubmed)
Abstract：
UNASSIGNED: Female athletes are at increased risk for anterior cruciate ligament (ACL) injuries. The influence of hormonal variation on female ACL injury risk remains ill-defined. Recent data suggests that the collagen-degrading menstrual hormone relaxin may cyclically impact female ACL tissue quality. This review aims to identify any correlation between menstrual relaxin peaks and rates of female ACL injury.
UNASSIGNED: A systematic review was performed, utilizing the MEDLINE, EMBASE, and CINAHL databases. Included studies had to directly address relaxin/female ACL interactions. The primary outcome variable was relaxin proteolysis of the ACL, at cellular, tissue, joint, and whole-organism levels. The secondary outcome variable was any discussed method of moderating relaxin levels, and the clinical results if available.
UNASSIGNED: AllThe numerous relaxin receptors on female ACLs upregulate local collagenolysis and suppress local collagen production. Peak serum relaxin concentrations (SRC) occur during menstrual cycle days 21-24; a time phase associated with greater risk of ACL injury. Oral contraceptives (OCPs) reduce SRC, with a potential ACLprotective effect.
UNASSIGNED: A reasonable correlative and plausible causative relationship exists between peak relaxin levels and increased risk of ACL injury in females, and further investigation is warranted. Level of Evidence: III.
UNASSIGNED: A systematic review was performed, utilizing the MEDLINE, EMBASE, and CINAHL databases. Included studies had to directly address relaxin/female ACL interactions. The primary outcome variable was relaxin proteolysis of the ACL, at cellular, tissue, joint, and whole-organism levels. The secondary outcome variable was any discussed method of moderating relaxin levels, and the clinical results if available.
UNASSIGNED: AllThe numerous relaxin receptors on female ACLs upregulate local collagenolysis and suppress local collagen production. Peak serum relaxin concentrations (SRC) occur during menstrual cycle days 21-24; a time phase associated with greater risk of ACL injury. Oral contraceptives (OCPs) reduce SRC, with a potential ACLprotective effect.
UNASSIGNED: A reasonable correlative and plausible causative relationship exists between peak relaxin levels and increased risk of ACL injury in females, and further investigation is warranted. Level of Evidence: III.
摘要：
■女运动员前交叉韧带（ACL）损伤的风险增加。激素变化对女性ACL损伤风险的影响仍然不明确。最近的数据表明，降解胶原蛋白的月经激素松弛素可能会周期性影响女性ACL组织质量。这篇综述旨在确定月经松弛素峰值与女性ACL损伤率之间的任何相关性。
■进行了系统评价，利用MEDLINE，EMBASE,和CINAHL数据库。纳入的研究必须直接解决松弛素/女性ACL相互作用。主要结果变量是ACL的松弛素蛋白水解，在细胞，组织,接头,和整个有机体的水平。次要结果变量是任何讨论过的调节松弛素水平的方法，和临床结果，如果有的话。
■所有雌性ACL上的众多松弛素受体上调局部胶原分解并抑制局部胶原生成。峰值血清松弛素浓度（SRC）出现在月经周期第21-24天；与ACL损伤风险更大相关的时间阶段。口服避孕药（OCPs）降低SRC，具有潜在的ACL保护作用。
■松弛素峰值水平与女性ACL损伤风险增加之间存在合理的相关性和似是而非的因果关系，需要进一步调查。证据等级：III。
■进行了系统评价，利用MEDLINE，EMBASE,和CINAHL数据库。纳入的研究必须直接解决松弛素/女性ACL相互作用。主要结果变量是ACL的松弛素蛋白水解，在细胞，组织,接头,和整个有机体的水平。次要结果变量是任何讨论过的调节松弛素水平的方法，和临床结果，如果有的话。
■所有雌性ACL上的众多松弛素受体上调局部胶原分解并抑制局部胶原生成。峰值血清松弛素浓度（SRC）出现在月经周期第21-24天；与ACL损伤风险更大相关的时间阶段。口服避孕药（OCPs）降低SRC，具有潜在的ACL保护作用。
■松弛素峰值水平与女性ACL损伤风险增加之间存在合理的相关性和似是而非的因果关系，需要进一步调查。证据等级：III。
